Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy

Date

14 Sep 2024

Session

Poster session 01

Topics

Immunotherapy

Tumour Site

Cervical Cancer

Presenters

Li Xiaoling Li

Citation

Annals of Oncology (2024) 35 (suppl_2): S544-S595. 10.1016/annonc/annonc1592

Authors

L.X. Li, L. Ai, S. Liu, X. Huang, J. Lu

Author affiliations

  • Oncology, General Hospital of Heilongjiang Province Agricultural Land Reclamation Bureau, 150088 - Harbin/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 723P

Background

Recurrent/ metastatic (R/M) cervical cancer (CC) patients who failed previous therapy has limited treatment options, especially in those progressed on previous immunotherapy. Cadonilimab (AK104, a PD-1/CTLA-4 bi-specific antibody) has showed promising anti-tumor activity in R/M CC in those failed standard platinum-based chemotherapy. This study explored the efficacy and safety of AK104 plus chemotherapy to enhance tumor control in persistent R/M CC patients who failed previous immuno/chemotherapy.

Methods

This phase II study recruited patients with histologically confirmed CC who had failed previous immuno/chemotherapy for R/M disease. All patients received AK104 (10mg/kg, Q3W) with 4-6 cycles of investigator's choice of chemotherapy. The primary endpoint is ORR and PFS per RECIST1.1. The secondary endpoints includes DCR, OS and AE (CTCAE 5.0).

Results

By April 1, 2024, 21 patients were enrolled (median age: 52). All had history of radiotherapy (postoperative adjuvant or radical radiotherapy). For R/M disease, all patients had received previous platinum-based chemotherapy, and eight of them were treated with PD-1 inhibitors. The median follow-up was 9.4 months (range: 2.4-14.1). Of 21 patients, the ORR and DCR was 52.4% (11/21) and 95.2% (20/21), respectively. The mPFS was 6.2 months (95%CI[2.6-9.8]), the mPFS of 2nd and ≥ 3rd line treatment was 6.2 and 4.8 months, respectively. Median OS was not mature. In patients progressed on previous PD-1 inhibitors, 2 achieved partial response and 5 had stable disease, with the ORR of 25% (2/8) and DCR of 87.5% (7/8). 28.6% (6/21) of the patients had grade 3 AEs (4 leukocyte reduction, 1 anemia, 1 rash).

Conclusions

This study evaluated the efficacy and safety of AK104 plus chemotherapy on R/M CC patients who had failed previous immuno/chemotherapy. Our results showed preliminary improved efficacy comparing to previous monotherapy (COMPASSION-03 study, ORR of 32.3%). This demonstrated the promising anti-tumor effectiveness of AK104 in patients who failed previous immunotherapy, the potential of reversing drug resistance and good safety. Further studies in larger populations are warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

X.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.